Vince & Associates Clinical Research Opens Dedicated Neuropsychiatric Research Center
Vince & Associates Clinical Research announces the opening of their new, dedicated Neuropsychiatric Research Center in Overland Park, KS. This research facility supports the needs of the pharmaceutical and biotechnology sectors by providing effective study recruitment, medical management and oversight in study volunteers across a range of neuropsychiatric disorders including both acute and chronic schizophrenia.
“While Vince and Associates has been conducting clinical trials in schizophrenia over the past decade, this dedicated unit will allow us to better serve the needs of both study volunteers and our biopharmaceutical clients,” said Dr. Brad Vince, President and Medical Director.
Debra Kelsh, MD, a Board-Certified Psychiatrist and an Investigator in over 300 clinical trials, will serve as Medical Director of the new Neuropsychiatric Research Center. “The safety and security of our study volunteers was highly emphasized during the design of the unit,” said Dr. Kelsh.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
